Collegium Pharmaceutical, Inc COLL
We take great care to ensure that the data presented and summarized in this overview for COLLEGIUM PHARMACEUTICAL, INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding COLL
View all-
Black Rock Inc. New York, NY5.79MShares$179 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.64MShares$81.2 Million1.79% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.35MShares$72.3 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA2.14MShares$66 Million0.15% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.66MShares$51 Million0.1% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.65MShares$50.7 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA1.49MShares$45.8 Million0.01% of portfolio
-
State Street Corp Boston, MA1.37MShares$42.3 Million0.0% of portfolio
-
Fuller & Thaler Asset Management, Inc. San Mateo, CA1.37MShares$42.2 Million0.21% of portfolio
-
Rubric Capital Management LP New York, NY1.25MShares$38.5 Million1.35% of portfolio
Latest Institutional Activity in COLL
Top Purchases
Top Sells
About COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Insider Transactions at COLL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 04
2025
|
Nancy Lurker Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,726
+50.0%
|
-
|
|
Jan 10
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
27,500
-9.73%
|
$907,500
$33.25 P/Share
|
|
Jan 10
2025
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
27,500
+15.79%
|
$577,500
$21.34 P/Share
|
|
Nov 12
2024
|
Vikram Karnani President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
105,972
+50.0%
|
-
|
|
Sep 13
2024
|
Thomas B Smith EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,593
-15.13%
|
$345,348
$36.62 P/Share
|
|
Sep 06
2024
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
977
-0.81%
|
$36,149
$37.46 P/Share
|
|
Sep 05
2024
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
19,248
-7.02%
|
$731,424
$38.66 P/Share
|
|
Jun 03
2024
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
25,000
-7.64%
|
$800,000
$32.89 P/Share
|
|
May 28
2024
|
Colleen Tupper EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
19,710
-13.09%
|
$670,140
$34.21 P/Share
|
|
May 24
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
56,807
-34.91%
|
$1,874,631
$33.98 P/Share
|
|
May 24
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
23,791
+12.76%
|
$570,984
$24.03 P/Share
|
|
May 23
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
51,209
-26.93%
|
$1,689,897
$33.82 P/Share
|
|
May 23
2024
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
51,209
+21.22%
|
$1,229,016
$24.03 P/Share
|
|
May 16
2024
|
Garen G Bohlin Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+12.79%
|
-
|
|
May 16
2024
|
Michael Thomas Heffernan Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+14.46%
|
-
|
|
May 16
2024
|
Rita J. Balice Gordon Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+14.2%
|
-
|
|
May 16
2024
|
John A. Fallon Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+12.3%
|
-
|
|
May 16
2024
|
John Gordon Freund Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+12.79%
|
-
|
|
May 16
2024
|
Neil F. Mc Farlane Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+13.48%
|
-
|
|
May 16
2024
|
Gwen A Melincoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,693
+12.79%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 730K shares |
|---|---|
| Exercise of conversion of derivative security | 131K shares |
| Payment of exercise price or tax liability | 220K shares |
|---|---|
| Open market or private sale | 250K shares |